Table Info

Table 3.

Drug-likeness profile of ligands

Sl. No.	Molecular wt. (g/mol)	HBA	HBD	TPSA (Å)²	Log P	Bioavailability	Log S	Csp³	RB	MR	Lipinski violations
1	598.66	9	3	156.7	3.46	0.17	–4.5	0.48	18	159.06	2
2	519.68	5	4	150.7	2.06	0.55	–4.12	0.81	14	144.39	1
3	894.11	8	4	178.72	5.63	0.17	–9.14	0.52	22	262.84	2
4	597.64	9	8	310.6	–3.17	0.17	0.65	0.57	20	146.7	3
5	883	10	4	193.1	5.05	0.17	–8.41	0.39	17	251.54	2

Sl.: serial number

Declarations

Acknowledgments

The authors are heartily thankful to the management of ISF College of Pharmacy for constant encouragement, support, and motivation.

Author contributions

AC: Data curation. AS: Investigation. PAC: Writing—original article, Writing—editing and review.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not Applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Chakraborty I, Maity P. COVID-19 outbreak: migration, effects on society, global environment and prevention. Sci Total Environ. 2020;728:138882. [DOI] [PubMed] [PMC]

Ma Y, Frutos-Beltrán E, Kang D, Pannecouque C, De Clercq E, Menéndez-Arias L, et al. Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. Chem Soc Rev. 2021;50:4514–40. [DOI] [PubMed]

Machhi J, Herskovitz J, Senan AM, Dutta D, Nath B, Oleynikov MD, et al. The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections. J Neuroimmune Pharmacol. 2020;15:359–86. [DOI] [PubMed] [PMC]

Vilas Boas LCP, Campos ML, Berlanda RLA, de Carvalho Neves N, Franco OL. Antiviral peptides as promising therapeutic drugs. Cell Mol Life Sci. 2019;76:3525–42. [DOI] [PubMed] [PMC]

Rietdijk J, Tampere M, Pettke A, Georgiev P, Lapins M, Warpman-Berglund U, et al. A phenomics approach for antiviral drug discovery. BMC Biol. 2021;19:156. [DOI] [PubMed] [PMC]

Negru PA, Radu AF, Vesa CM, Behl T, Abdel-Daim MM, Nechifor AC, et al. Therapeutic dilemmas in addressing SARS-CoV-2 infection: favipiravir versus remdesivir. Biomed Pharmacother. 2022;147:112700. [DOI] [PubMed] [PMC]

Schütz D, Ruiz-Blanco YB, Münch J, Kirchhoff F, Sanchez-Garcia E, Müller JA. Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv Drug Deliv Rev. 2020;167:47–65. [DOI] [PubMed] [PMC]

Lou Z, Sun Y, Rao Z. Current progress in antiviral strategies. Trends Pharmacol Sci. 2014;35:86–102. [DOI] [PubMed] [PMC]

Diao L, Meibohm B. Pharmacokinetics and pharmacokinetic–pharmacodynamic correlations of therapeutic peptides. Clin Pharmacokinet. 2013;52:855–68. [DOI] [PubMed]

10.

Cabrele C, Martinek TA, Reiser O, Berlicki Ł. Peptides containing β-amino acid patterns: challenges and successes in medicinal chemistry. J Med Chem. 2014;57:9718–39. [DOI] [PubMed]

11.

Mousavi Maleki MS, Rostamian M, Madanchi H. Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2. Expert Rev Anti Infect Ther. 2021;19:1205–17. [DOI] [PubMed] [PMC]

12.

Bansal R, Mohagaonkar S, Sen A, Khanam U, Rathi B. In-silico study of peptide-protein interaction of antimicrobial peptides potentially targeting SARS and SARS-CoV-2 nucleocapsid protein. In Silico Pharmacol. 2021;9:46. [DOI] [PubMed] [PMC]

13.

Chianese A, Zannella C, Monti A, De Filippis A, Doti N, Franci G, et al. The broad-spectrum antiviral potential of the amphibian peptide AR-23. Int J Mol Sci. 2022;23:883. [DOI] [PubMed] [PMC]

14.

Zannella C, Chianese A, Palomba L, Marcocci ME, Bellavita R, Merlino F, et al. Broad-spectrum antiviral activity of the amphibian antimicrobial peptide temporin L and its analogs. Int J Mol Sci. 2022;23:2060. [DOI] [PubMed] [PMC]

15.

Nireeksha N, Gollapalli P, Varma SR, Hegde MN, Kumari NS. Utilizing the potential of antimicrobial peptide LL-37 for combating SARS-COV-2 viral load in saliva: an in silico analysis. Eur J Dent. 2022;16:478–87. [DOI] [PubMed] [PMC]

16.

Ali GS, Ozdemir B, Selamoglu Z. A review of severe acute respiratory syndrome coronavirus 2 and pathological disorders in patients. J Pharm Care. 2021;9:141–7. [DOI]

17.

Rehman MFU, Akhter S, Batool AI, Selamoglu Z, Sevindik M, Eman R, et al. Effectiveness of natural antioxidants against SARS-CoV-2? Insights from the in-silico world. Antibiotics (Basel). 2021;10:1011. [DOI] [PubMed] [PMC]

18.

Luan B, Huynh T, Cheng X, Lan G, Wang HR. Targeting proteases for treating COVID-19. J Proteome Res. 2020;19:4316–26. [DOI] [PubMed] [PMC]

19.

Zhang Y, Zhang S, Zhang Z, Ji L, Zhang J, Wang Q, et al. Recent progress on NIR-II photothermal therapy. Front Chem. 2021;9:728066. [DOI] [PubMed] [PMC]

20.

Yu Z, Chan WK, Zhang Y, Tan TTY. Near-infrared-II activated inorganic photothermal nanomedicines. Biomaterials. 2021;269:120459. [DOI] [PubMed]

21.

Mariewskaya KA, Tyurin AP, Chistov AA, Korshun VA, Alferova VA, Ustinov AV. Photosensitizing antivirals. Molecules. 2021;26:3971. [DOI] [PubMed] [PMC]

22.

A randomized, open, controlled clinical study to evaluate the efficacy of ASC09F and ritonavir for 2019-nCoV pneumonia [Internet]. Bethesda (MD): National Library of Medicine; c2020 [updated 2020 Mar 17; cited 2022 Sep 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT04261270

23.

Elmekaty EZI, Alibrahim R, Hassanin R, Eltaib S, Elsayed A, Rustom F, et al. Darunavir-cobicistat versus lopinavir-ritonavir in the treatment of COVID-19 infection (DOLCI): a multicenter observational study. PLoS One. 2022;17:e0267884. [DOI] [PubMed] [PMC]

24.

Lockbaum GJ, Henes M, Lee JM, Timm J, Nalivaika EA, Thompson PR, et al. Pan-3C protease inhibitor rupintrivir binds SARS-CoV-2 main protease in a unique binding mode. Biochemisty. 2021;60:2925–31. [DOI] [PubMed] [PMC]

25.

Sui A, Zhong Y, Demetriades AM, Shen J, Su T, Yao Y, et al. ATN-161 as an integrin α5β1 antagonist depresses ocular neovascularization by promoting new vascular endothelial cell apoptosis. Med Sci Monit. 2018;24:5860–73. [DOI] [PubMed] [PMC]

26.

Bersoff-Matcha SJ, Cao K, Jason M, Ajao A, Jones SC, Meyer T, et al. Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration Adverse Event Reporting System. Ann Intern Med. 2017;166:792–8. [DOI] [PubMed]

27.

Rizza SA, Talwani R, Nehra V, Temesgen Z. Boceprevir. Drugs Today (Barc). 2011;47:743–51. [DOI] [PubMed]

28.

Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979–87. [DOI] [PubMed] [PMC]

29.

Ma C, Sacco MD, Hurst B, Townsend JA, Hu Y, Szeto T, et al. Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease. Cell Res. 2020;30:678–92. [DOI] [PubMed] [PMC]

30.

E Lohning A, M Levonis S, Williams-Noonan B, S Schweiker S. A practical guide to molecular docking and homology modelling for medicinal chemists. Current Topics in Medicinal Chemistry. 2017;18:2023–40. [DOI] [PubMed]

31.

Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61. [DOI] [PubMed] [PMC]

32.

Jejurikar BL, Rohane SH. Drug designing in Discovery Studio. Asian J Res Chem. 2021;14:135–8. [DOI]